Skip to navigation Skip to content

Chronic myelomonocytic leukaemia program in Pharmaceutical Benefits Scheme (PBS) 012-22062453

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised azacitidine and decitabine+cedazuridine for patients with chronic myelomonocytic leukaemia (CMML).

Chronic myelomonocytic leukaemia and listing dates

Chronic myelomonocytic leukaemia is a chronic blood cancer in which a person’s bone marrow creates too many monocytes, a type of white blood cell.

Listing dates are:

  • azacitidine - 1 February 2011, and
  • decitabine+cedazuridine - 1 October 2022

For more information, see Written Authority Required Drugs.

Enquiries

  • Transfer enquiries about prescription arrangements for azacitidine to the PBS Complex Drugs Programs team and choose the option relevant to the condition treated
  • Transfer enquiries about prescription arrangements for decitabine+cedazuridine to PBS authority approvals

The Resources page contains links to application forms, contact details, item and restriction codes, the PBS schedule and the Services Australia website.

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)

Process telephone Authority approval application

Processing Complex Authority Required Listings

Written Authority Required Drugs